Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Creative Biolabs is one of the world’s leading contract organizations (CRO) that has extensive experience in preclinical drug discovery. Our employees are at the core of our success, with the ambition to improving health and increasing access to quality health solutions worldwide. We believe when curious, courageous and collaborative people like you are brought together, a big difference will be made for the development of innovate medicines.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant monoclonal antibody to HBV. Libivirumab is a human monoclonal antibody directed against the hepatitis B virus.
Hepatitis B surface antigen
IgG1 - kappa
The details of the immunogen for this antibody are not available.
Suitable for use in WB, ELISA, IP, FC, FuncS, Neut, IF and most other immunological methods.
Tested positive against native HBV antigen.
Immunoglobulin G, anti- (hepatitis B surface antigen)(human monoclonal 17.1.41 heavy chain), disulfide with human monoclonal 17.1.41 kappa-chain, dimer
Predicted N terminal
H chain: QVKLLES; L chain: ELVMTQ
>95%, by SDS-PAGE with silver staining, under reducing conditions.
Store at -20°C. Avoid multiple freeze/thaw cycles.
This is a human monoclonal antibody directed against the hepatitis B virus.
HBV (HBV) infection induces a disease state which manifests itself in a variety of ways, characterized by the extent of liver damage, inflammation and viral persistence. HBV infection is also associated with a 100 fold increased risk of hepatocellular carcinoma and currently infects over 250 million people worldwide. HBV has a partially double stranded 3.2 kilobase DNA genome which contains four open reading frames. One of these encodes a 154 amino acid protein called the HBx protein. HBx has been shown to be a transcriptional transactivator of both viral and cellular promoters. Lacking a DNA binding domain and nuclear localization signal, HBx is believed to exert transcriptional activity through protein protein interaction.
HBsAg; Hep B surface antigen; Hepatitis B Virus major surface antigen; Hepatitis B virus S antigen; Large envelope protein; Large surface protein; LHB; Major surface antigen